汇宇制药(688553.SH)子公司产品获得境外上市许可

智通财经2025-07-25

智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554752682?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-25 16:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554752682","market":"sh","top_or_hot":-1,"title":"汇宇制药(688553.SH)子公司产品获得境外上市许可","media":"智通财经","content":"<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1321948.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>汇宇制药(688553.SH)子公司产品获得境外上市许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n汇宇制药(688553.SH)子公司产品获得境外上市许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-25 16:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1321948.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1321948.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1321948.html","article_id":"2554752682","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554752682","pubTimestamp":1753430551,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的上市许可，有利于公司在国际市场产品管线的丰富，提升市场的品牌形象，持续拓展国际业务的广度和深度，为国际市场的可持续发展进一步夯实了基础。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688553":"汇宇制药","BK0239":"医药制造"},"translate_title":"Huiyu Pharmaceutical (688553. SH) subsidiary products obtained overseas marketing authorization","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1},"content_text":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的上市许可，有利于公司在国际市场产品管线的丰富，提升市场的品牌形象，持续拓展国际业务的广度和深度，为国际市场的可持续发展进一步夯实了基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554752682","isCrawlerRequest":true}